Summit Therapeutics Inc. and Lunit Inc. announced a research agreement on October 24, 2026, to apply Lunit's AI-powered pathology platform, Lunit SCOPE IO, to tumor microenvironment analysis in support of Summit's ivonescimab immuno-oncology development programs.

Key Highlights

  • Research focus: Lunit SCOPE IO will be applied to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment features linked to ivonescimab therapies.
  • Ivonescimab description: Summit describes ivonescimab (SMT112 in its license territories) as "a novel, potential first-in-class investigational bispecific antibody" targeting both PD-1 and VEGF in a single molecule.
  • Clinical scope: According to the filing, there are currently 17 Phase III clinical studies announced, ongoing, or completed studying ivonescimab, five of which are Summit-sponsored global studies.
  • Phase III readouts: The filing states that five Phase III ivonescimab trials have read out to date, all five with positive data, including four in non-small cell lung cancer (NSCLC) and one in biliary tract cancer.
  • Regulatory status: The filing notes ivonescimab "is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe."
  • Research-use limitation: Lunit SCOPE products are designated for research use only and are "not for use in diagnostic procedures or decisions," according to the filing.
  • No clinical outcome data: The filing states explicitly that "no clinical outcome data are being announced as part of this release."

Lunit SCOPE IO to Support Ivonescimab Biomarker and Tumor Microenvironment Research

According to the filing, the research agreement centers on using Lunit SCOPE IO to analyze H&E whole-slide images from Summit's ivonescimab development programs. The companies disclosed that their aim is to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and "a deeper biological understanding of response to ivonescimab therapies." The filing notes that Lunit SCOPE IO is designed to enable "scalable assessment of tumor microenvironment features without requiring additional stains or assays."

Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit, was quoted in the filing as stating: "Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations." Brandon Suh, Lunit CEO, was quoted saying the platform can help "biopharma partners better understand which patients may benefit from immuno-oncology therapies and why." The filing characterizes the agreement as reflecting "the growing importance of computational pathology in oncology drug development."

The filing describes ivonescimab as displaying "unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF," and attributes this characterization to Summit. Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK). Summit's sponsored Phase III program spans NSCLC (HARMONi, HARMONi-3, HARMONi-7), colorectal cancer (HARMONi-GI3), and urothelial carcinoma (HARMONi-GU1), according to the disclosure. The filing states that the companies "expect the work to generate tumor microenvironment insights that may inform future translational research, exploratory biomarker strategies, and clinical development planning."

What Was Disclosed

Summit Therapeutics (NASDAQ:SMMT) and Lunit (KRX: 328130) disclosed a research agreement to apply Lunit's AI pathology platform to H&E images from ivonescimab studies, targeting tumor microenvironment analysis and biomarker discovery. No clinical outcome data were announced.